AsPC-1 Cells

The AsPC1 cell line, derived from a 62-year-old female patient with adenocarcinoma of pancreas and metastases to several abdominal organs, has become a pivotal model for studying pancreatic cancer, one of the most aggressive and lethal malignancies. They display a high degree of invasiveness compared to other pancreatic cancer cell lines, which makes them particularly useful for studies on cancer metastasis and tumor invasion. AsPC1 cells have been instrumental in understanding the metabolic pathways involved in pancreatic cancer, including glutamine and glycerophospholipid metabolism. AsPC1 cells have been used to investigate the function of matrix metalloproteinases (MMPs) in metastasis, a crucial component of the biology of pancreatic cancer. AsPC1 cells have further been used to evaluate the efficacy of treatments such as the HDAC inhibitor AR-42 and the antimitotic and STAT3 inhibitor LTP-1, demonstrating the potential of these compounds to suppress tumor growth and induce apoptosis in pancreatic cancer cell lines. The development of xenograft models using AsPC1 cells has allowed researchers to study pancreatic cancer in a more physiologically relevant context and have provided valuable insights into the transformation of normal human pancreatic duct cells into adenocarcinomas. AsPC1 cells continue to be a valuable resource for exploring the therapeutic bispecific pathways and intracellular tumor antigens associated with pancreatic cancer.